Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592830569> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2592830569 endingPage "4110" @default.
- W2592830569 startingPage "4110" @default.
- W2592830569 abstract "4110 Background: Erlotinib (Tarceva) is a reversible inhibitor of HER1/EGFR tyrosine kinase. It has demonstrated antitumor activity in various epithelial malignancies and additive antitumor effect when combined with chemotherapy drugs. The purpose of this trial was to evaluate the tolerability and preliminary activity of escalating doses of erlotinib given in combination with standard-dose gemcitabine (GEM 1000 mg/m2). Methods: Eligible patients included those with advanced pancreatic carcinoma or other malignancies potentially responsive to GEM. In the escalating phase of the trial patients with pancreatic and non-pancreatic carcinomas were enrolled in sequential cohorts using 100 mg or 150 mg oral daily dosing of erlotinib. GEM 1000 mg/m2 was given weekly for 7 weeks (1st cycle), then weekly x 3 every 4 weeks (subsequent cycles). Preliminary results from the dose-escalating phase of this trial were previously reported (ASCO 2003). After establishing tolerability, additional gemcitabine-naïve patients with pancreatic cancer were enrolled. Overall, we have enrolled 14 patients with unresectable pancreatic carcinoma: 2 patients at the 100 mg dose level of erlotinib and 12 patients at the 150 mg dose level. Characteristics: measurable or evaluable disease, gender M/F 7/7, median age 66 yrs (range 45–82), median PS 90 % KS (range 80–100%). Results: 1 partial response (PR, 7%), 3 minor responses and 6 with stable disease for an overall disease control rate of 70 % (PR+SD), and 4 patients progressed (PD, 30%). The median duration of study treatment was 4 months (range from 2 to 12+) with 4 patients remaining on study treatment. The most common toxicities included skin rash, neutropenia, fatigue, nausea and diarrhea. The full PK analysis is ongoing and will be updated at the time of meeting. Conclusion: The erlotinib + gemcitabine combination appears promising, with a high rate of disease stabilization and acceptable toxicity profile seen in patients with unresectable pancreatic carcinoma. This combination is currently being compared to standard GEM therapy in a phase III randomized trial conducted by the NCIC. Supported by grant from OSI Pharmaceuticals. No significant financial relationships to disclose." @default.
- W2592830569 created "2017-03-16" @default.
- W2592830569 creator A5000921919 @default.
- W2592830569 creator A5001736304 @default.
- W2592830569 creator A5010296340 @default.
- W2592830569 creator A5011905014 @default.
- W2592830569 creator A5020802233 @default.
- W2592830569 creator A5035076837 @default.
- W2592830569 creator A5065671989 @default.
- W2592830569 creator A5066473113 @default.
- W2592830569 creator A5071957638 @default.
- W2592830569 creator A5080782233 @default.
- W2592830569 date "2004-07-15" @default.
- W2592830569 modified "2023-09-26" @default.
- W2592830569 title "Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial" @default.
- W2592830569 doi "https://doi.org/10.1200/jco.2004.22.90140.4110" @default.
- W2592830569 hasPublicationYear "2004" @default.
- W2592830569 type Work @default.
- W2592830569 sameAs 2592830569 @default.
- W2592830569 citedByCount "7" @default.
- W2592830569 countsByYear W25928305692021 @default.
- W2592830569 crossrefType "journal-article" @default.
- W2592830569 hasAuthorship W2592830569A5000921919 @default.
- W2592830569 hasAuthorship W2592830569A5001736304 @default.
- W2592830569 hasAuthorship W2592830569A5010296340 @default.
- W2592830569 hasAuthorship W2592830569A5011905014 @default.
- W2592830569 hasAuthorship W2592830569A5020802233 @default.
- W2592830569 hasAuthorship W2592830569A5035076837 @default.
- W2592830569 hasAuthorship W2592830569A5065671989 @default.
- W2592830569 hasAuthorship W2592830569A5066473113 @default.
- W2592830569 hasAuthorship W2592830569A5071957638 @default.
- W2592830569 hasAuthorship W2592830569A5080782233 @default.
- W2592830569 hasConcept C121608353 @default.
- W2592830569 hasConcept C126322002 @default.
- W2592830569 hasConcept C143998085 @default.
- W2592830569 hasConcept C197934379 @default.
- W2592830569 hasConcept C2776694085 @default.
- W2592830569 hasConcept C2777288759 @default.
- W2592830569 hasConcept C2778087573 @default.
- W2592830569 hasConcept C2778375690 @default.
- W2592830569 hasConcept C2778822529 @default.
- W2592830569 hasConcept C2779438470 @default.
- W2592830569 hasConcept C2780210213 @default.
- W2592830569 hasConcept C2780258809 @default.
- W2592830569 hasConcept C2909325608 @default.
- W2592830569 hasConcept C31760486 @default.
- W2592830569 hasConcept C71924100 @default.
- W2592830569 hasConcept C90924648 @default.
- W2592830569 hasConceptScore W2592830569C121608353 @default.
- W2592830569 hasConceptScore W2592830569C126322002 @default.
- W2592830569 hasConceptScore W2592830569C143998085 @default.
- W2592830569 hasConceptScore W2592830569C197934379 @default.
- W2592830569 hasConceptScore W2592830569C2776694085 @default.
- W2592830569 hasConceptScore W2592830569C2777288759 @default.
- W2592830569 hasConceptScore W2592830569C2778087573 @default.
- W2592830569 hasConceptScore W2592830569C2778375690 @default.
- W2592830569 hasConceptScore W2592830569C2778822529 @default.
- W2592830569 hasConceptScore W2592830569C2779438470 @default.
- W2592830569 hasConceptScore W2592830569C2780210213 @default.
- W2592830569 hasConceptScore W2592830569C2780258809 @default.
- W2592830569 hasConceptScore W2592830569C2909325608 @default.
- W2592830569 hasConceptScore W2592830569C31760486 @default.
- W2592830569 hasConceptScore W2592830569C71924100 @default.
- W2592830569 hasConceptScore W2592830569C90924648 @default.
- W2592830569 hasIssue "14_suppl" @default.
- W2592830569 hasLocation W25928305691 @default.
- W2592830569 hasOpenAccess W2592830569 @default.
- W2592830569 hasPrimaryLocation W25928305691 @default.
- W2592830569 hasRelatedWork W2032475800 @default.
- W2592830569 hasRelatedWork W2039780710 @default.
- W2592830569 hasRelatedWork W2059228450 @default.
- W2592830569 hasRelatedWork W2061577424 @default.
- W2592830569 hasRelatedWork W2150336457 @default.
- W2592830569 hasRelatedWork W2163866397 @default.
- W2592830569 hasRelatedWork W2168849655 @default.
- W2592830569 hasRelatedWork W2257468762 @default.
- W2592830569 hasRelatedWork W2421782557 @default.
- W2592830569 hasRelatedWork W2959913723 @default.
- W2592830569 hasVolume "22" @default.
- W2592830569 isParatext "false" @default.
- W2592830569 isRetracted "false" @default.
- W2592830569 magId "2592830569" @default.
- W2592830569 workType "article" @default.